Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

Ascidian's exon editing technology is designed to provide the durability of gene therapy by rewriting RNA, while sharply reducing the risks associated with direct DNA editing and gene replacement. This approach has the potential to treat patients with one dose of an RNA exon editor. Roche's shares have lost 3.4% year to date against the industry's growth of 20.4%. The acquisition gave Roche access to Carmot's differentiated portfolio of incretins, including CT-388, the lead asset, phase-II ready, dual GLP-1 ...